JHCC(002484)2024-04-25 10:02Financial Performance - The company's operating revenue for Q1 2024 was ¥1,051,101,283.76, a decrease of 11.12% compared to ¥1,182,598,365.60 in the same period last year [24]. - Net profit attributable to shareholders was ¥136,908,045.59, down 11.32% from ¥154,383,125.06 year-on-year [24]. - The net cash flow from operating activities was ¥104,341,039.06, reflecting a decline of 6.75% compared to ¥111,898,626.09 in the previous year [24]. - Basic earnings per share decreased to ¥0.1620, down 11.76% from ¥0.1836 in the same period last year [24]. - Total operating revenue for Q1 2024 was CNY 1,051,101,283.76, a decrease of 11.1% compared to CNY 1,182,598,365.60 in the same period last year [43]. - Net profit for the first quarter was approximately ¥138.5 million, a decrease of 10.3% compared to ¥154.4 million in the same period last year [44]. - The total comprehensive income for the first quarter was approximately ¥122.2 million, down from ¥160.3 million year-over-year [45]. Cash Flow - Net cash flow from investing activities increased by CNY 38,269,297.71, a growth of 40.36%, mainly due to changes in structured financial products and fixed asset investments [10]. - Net cash flow from financing activities decreased by CNY 65,982,231.18, a decline of 231.41%, primarily due to increased exercise payments and stock repurchases [10]. - The net increase in cash and cash equivalents rose by CNY 223,801,782.04, an increase of 30.09%, resulting from the aforementioned changes [10]. - Cash outflow from operating activities totaled CNY 688,172,055.01, compared to CNY 794,615,171.13 in the previous year, indicating a reduction of 13.4% [36]. - The company reported a net cash outflow from investment activities of CNY -56,562,149.18, an improvement from CNY -94,831,446.89 in the prior year [36]. - Cash inflow from financing activities was CNY 61,192,280.96, an increase from CNY 51,389,922.40 year-over-year [36]. - The ending cash and cash equivalents balance was approximately ¥967.7 million, down from ¥743.9 million year-over-year [48]. Assets and Equity - Total assets at the end of the reporting period were ¥7,360,178,926.66, an increase of 1.34% from ¥7,263,050,307.80 at the end of the previous year [24]. - Shareholders' equity attributable to the parent company increased by 1.67% to ¥5,612,717,643.85 from ¥5,520,321,750.53 [24]. - The total current assets amounted to ¥4,437,528,612.05, a marginal increase from ¥4,416,704,764.34 [24]. - The company’s long-term equity investments were valued at ¥142,323,925.59, showing a slight decrease from ¥142,391,771.67 [24]. - The company’s cash and cash equivalents were reported at ¥1,029,798,346.21, slightly down from ¥1,033,226,187.18 [24]. - The company experienced a foreign exchange loss impacting cash and cash equivalents of approximately ¥17.0 million [48]. Expenses and Costs - Total operating costs were approximately ¥929.5 million, down 7.6% from ¥1,006.0 million year-over-year [44]. - Research and development expenses increased to approximately ¥66.5 million, up 15.6% from ¥57.5 million year-over-year [44]. - Financial expenses decreased by CNY 7,617,575.42, a decline of 158.64%, mainly due to changes in exchange gains and losses [10]. Other Income and Investments - Other income increased by CNY 22,597,301.79, an increase of 197.62%, primarily due to an increase in VAT deductions [10]. - Investment income rose by CNY 3,604,193.09, an increase of 330.75%, mainly due to increased sales and gross profit from an associated company [10]. - The company reported a non-operating income of ¥8,479,968.01 related to government subsidies [24]. Future Outlook - The net increase in policyholder deposits and investment funds was not specified but is a key focus area for future growth [36]. - The company aims to enhance its market expansion strategies and product development initiatives in the upcoming quarters [36]. - The company is committed to implementing new accounting standards starting from 2024, which may impact future financial reporting [38].